Conte J E, Golden J A, Kipps J, Lin E T, Zurlinden E
Infectious Diseases Research Laboratory, Department of Epidemiology and Biostatistics, University of California-San Francisco, 350 Parnassus Ave., San Francisco, CA 94117, USA.
Antimicrob Agents Chemother. 2001 Oct;45(10):2891-6. doi: 10.1128/AAC.45.10.2891-2896.2001.
Our objective was to study the steady-state plasma and intrapulmonary orally administered ethambutol concentrations in healthy volunteers and subjects with AIDS. Ethambutol (15 mg/kg of body weight) was administered orally once daily to 10 men with AIDS, 10 healthy men, 10 women with AIDS, and 10 healthy women. The mean (+/-standard deviation [SD]) CD4 cell count for the 20 subjects with AIDS was (350 +/- 169) x 10(6) cells per liter. Blood was obtained for drug assay 2 h after the last dose and at the completion of bronchoalveolar lavage, performed 4 h after the last dose. Standardized bronchoscopy was performed without systemic sedation. The volume of epithelial lining fluid (ELF) was calculated by the urea dilution method. The total number of alveolar cells (AC) was counted in a hemocytometer, and differential cell counting was performed after cytocentrifugation. Ethambutol was measured by a new, sensitive and specific liquid chromotography-mass spectrometry method. The presence of AIDS, as defined in this study, or gender was without significant effect on the concentrations of ethambutol in plasma at 2 or 4 h or in ELF at 4 h following the last dose. Plasma drug concentrations (mean +/- SD) at 2 and 4 h were 2.1 +/- 1.2 and 2.1 +/- 0.8 microg/ml, respectively, and both values were not significantly different from the concentration of ethambutol in ELF at 4 h (2.2 +/- 1.1 microg/ml). The concentration of ethambutol was significantly greater in AC in all four groups (range, 44.5 +/- 15.6 to 82.0 +/- 39.4 microg/ml) than in ELF or plasma and was approximately 30 to 240 times the reported MIC for ethambutol-susceptible strains of Mycobacterium tuberculosis. The AC ethambutol concentration (mean +/- SD) in the smoking women (97.2 +/- 32.1 microg/ml) was more than twice the concentration in all other nonsmoking subjects (45.2 +/- 16.8 microg/ml) combined (P < 0.05). Two- and 4-h concentrations of ethambutol in plasma were not affected by AIDS status or gender. The high AC/plasma and AC/ELF concentration ratios suggest that substantial antimycobacterial activity resides in these cells. The data confirm earlier observations of active transport ex vivo of ethambutol into pulmonary macrophages.
我们的目的是研究健康志愿者和艾滋病患者口服乙胺丁醇后的稳态血浆浓度和肺内浓度。对10名男性艾滋病患者、10名健康男性、10名女性艾滋病患者和10名健康女性,每日口服一次乙胺丁醇(15mg/kg体重)。20名艾滋病患者的平均(±标准差[SD])CD4细胞计数为(350±169)×10⁶个/升。在最后一剂给药后2小时以及最后一剂给药后4小时进行支气管肺泡灌洗结束时采集血样用于药物测定。在无全身镇静的情况下进行标准化支气管镜检查。采用尿素稀释法计算上皮衬液(ELF)的体积。在血细胞计数器中对肺泡细胞(AC)总数进行计数,并在细胞离心后进行细胞分类计数。采用一种新的、灵敏且特异的液相色谱 - 质谱法测定乙胺丁醇。本研究中定义的艾滋病状态或性别对最后一剂给药后2小时或4小时血浆中乙胺丁醇浓度或4小时ELF中乙胺丁醇浓度均无显著影响。2小时和4小时时血浆药物浓度(均值±SD)分别为2.1±1.2和2.1±0.8μg/ml,这两个值与4小时时ELF中乙胺丁醇浓度(2.2±1.1μg/ml)均无显著差异。在所有四组中,AC中乙胺丁醇浓度(范围为44.5±15.6至82.0±39.4μg/ml)显著高于ELF或血浆中的浓度,约为结核分枝杆菌乙胺丁醇敏感菌株报告的最低抑菌浓度的30至240倍。吸烟女性的AC乙胺丁醇浓度(均值±SD)(97.2±32.1μg/ml)是所有其他非吸烟受试者(45.2±16.8μg/ml)总和的两倍多(P<0.05)。血浆中乙胺丁醇2小时和4小时的浓度不受艾滋病状态或性别的影响。高AC/血浆和AC/ELF浓度比表明这些细胞具有大量抗分枝杆菌活性。这些数据证实了早期关于乙胺丁醇在体外主动转运至肺巨噬细胞的观察结果。